Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cipla
Citi
Mallinckrodt
UBS
McKinsey
Cerilliant
Moodys
Farmers Insurance

Generated: May 21, 2018

DrugPatentWatch Database Preview

M.V.I.-12 Drug Profile

« Back to Dashboard

Which patents cover M.v.i.-12, and when can generic versions of M.v.i.-12 launch?

M.v.i.-12 is a drug marketed by Hospira and Teligent Pharma Inc and is included in two NDAs.

The generic ingredient in M.V.I.-12 is ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e. There are six drug master file entries for this compound. Additional details are available on the ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine; riboflavin 5'-phosphate sodium; thiamine; vitamin a; vitamin e profile page.
Summary for M.V.I.-12
You have an error in your SQL syntax; check the manual that corresponds to your MariaDB server version for the right syntax to use near 'SODIUM','THIAMINE','VITAMIN A','VITAMIN E') AND hsdb_drugname IS NOT NULL' at line 1
US Patents:0
Applicants:2
NDAs:2